FDA clears vibrating belt to boost brittle bones in women facing osteoporosis
The FDA has granted a clearance to its first prescription medical device to help treat low bone density, with a wearable vibrating belt designed for postmenopausal women.
The FDA has granted a clearance to its first prescription medical device to help treat low bone density, with a wearable vibrating belt designed for postmenopausal women.
Genentech is walking away from an 18-year relationship with AC Immune, handing back global rights to a pair of Alzheimer’s disease drug candidates after suffering a series of setbacks in the clinic.
Pharvaris’ preventative oral medicine for hereditary angioedema (HAE) has had its remaining clinical hold lifted by the FDA weeks after the treatment proved its worth in a phase 2 study.
Spinal cord stimulation has been available as a chronic pain treatment for decades, but even now, Medtronic—which was the first to make the implants commercially available in the late 1960s—is still improving on the technology.
Leadership at the FDA and the Centers for Medicare and Medicaid Services issued a joint statement to reiterate plans to increase the federal oversight of lab-developed tests, commonly known as LDTs.
Kyverna has nabbed another FDA fast-track designation for its lead asset, adding further momentum to its IPO roadshow days after declaring plans to go public.
The FDA this week published a safety notice alerting patients and healthcare providers to possible risks linked to certain shoulder joint replacement implants.
With Medtronic and Johnson & Johnson securing international approvals in the nascent domain of pulsed field ablation, Abbott is looking to join the party with its own approach for treating atrial fibrillation and other arrhythmias.
Following reports earlier this week that Apple had redesigned some versions of its eponymous smartwatch to remove them from the purview of a then-paused import ban, the tech giant has indeed begun selling altered versions of those Apple Watches in the U.S. as the ban takes effect once again.
Golden Biotechnology has shared updated data on its mushroom-derived drug candidate in metastatic pancreatic cancer, linking first-line use of the molecule to median overall survival (OS) of 14.1 months.